Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 134K 124K 114K 215K 14.78M 219K 1.48M 581K 7.22M 576K 563K 24.92M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.49M 16.18M 14.84M 28.09M 1.93B 28.58M 193M 75.78M 942M 75.15M 73.5M 3.25B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
18-12-20	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
18-01-10	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
16-09-27	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
16-08-29	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
16-08-10	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
16-07-08	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
16-06-08	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
16-03-29	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
16-03-22	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
16-03-21	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-11-19	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+1.08%	-3.93%	+48.03%	+160.13%	1,043B
JOHNSON & JOHNSON	+1.19%	-3.52%	+51.70%	+56.36%	602B
ABBVIE INC.	+4.21%	+1.79%	+33.48%	+87.04%	449B
ROCHE HOLDING AG	-0.06%	-1.49%	+29.03%	+23.64%	327B
NOVARTIS AG	+0.67%	-0.08%	+33.04%	+46.23%	279B
ASTRAZENECA PLC	-0.97%	-2.40%	+21.47%	+22.80%	264B
AMGEN INC.	+3.70%	+2.19%	+24.27%	+63.38%	201B
GILEAD SCIENCES, INC.	+3.49%	+1.08%	+24.08%	+76.58%	169B
PFIZER INC.	+1.29%	+3.67%	+2.15%	-30.78%	143B
Average	+0.90%	-0.68%	+29.69%	+56.15%	386.34B
Weighted average by Cap.	+0.96%	-1.82%	+37.35%	+82.80%

	2014	2015
Net sales	-	-
Net income	-38.52M -33.67M -31.14M -28.57M -54.07M -3.71B -55.01M -371M -146M -1.81B -145M -141M -6.26B	-6.84M -5.98M -5.53M -5.08M -9.61M -660M -9.78M -65.99M -25.92M -322M -25.71M -25.14M -1.11B
Net Debt	-45K -39.33K -36.38K -33.38K -63.18K -4.34M -64.27K -434K -170K -2.12M -169K -165K -7.31M	19.86M 17.36M 16.05M 14.73M 27.88M 1.91B 28.36M 191M 75.2M 934M 74.57M 72.93M 3.23B

Star Scientific, Inc. Stock Nasdaq

Stocks

US85517P1012

Pharmaceuticals

Valuation: Star Scientific, Inc.

Latest news : Star Scientific, Inc.

Analysts' recommendations: Star Scientific, Inc.

Other Pharmaceuticals

Financials

Company Profile

End-of-day quote Nasdaq Other stock markets
- ^USD	-